down arrow

Atea Pharmaceuticals, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US04683R1068
USD
3.62
0.19 (5.54%)

Dec 24

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

3.433.69

52 Week

2.464.02
Valuation
Technical
Day's Volume

CASH

379.36 k

Shareholding (Mar 2025)

FII

5.03%

Held by 50 FIIs

DII

64.43%

Held by 34 DIIs

Promoter

2.94%

How big is Atea Pharmaceuticals, Inc.?

22-Jun-2025

As of Jun 18, Atea Pharmaceuticals, Inc. has a market capitalization of 274.71 million and reported net sales of 0.00 million with a net profit of -139.48 million over the latest four quarters. The balance sheet as of Dec'24 shows shareholder's funds of 438.87 million and total assets of 464.67 million.

As of Jun 18, Atea Pharmaceuticals, Inc. has a market capitalization of 274.71 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -139.48 million during the same period.<BR><BR>As of Dec'24, the balance sheet shows shareholder's funds of 438.87 million and total assets of 464.67 million.

Read More

What does Atea Pharmaceuticals, Inc. do?

22-Jun-2025

Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing antiviral therapeutics. As of March 2025, it has a market cap of $274.71 million and reported a net profit loss of $34 million.

Overview:<BR>Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics in the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot:<BR>Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 274.71 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.03 <BR>Return on Equity: -33.93% <BR>Price to Book: 0.67<BR><BR>Contact Details:<BR>Address: 125 SUMMER STREET, 16TH FLOOR, BOSTON MA : 02110 <BR>Tel: 1 857 2048109 <BR>Fax: 1 302 6555049 <BR>Website: https://ateapharma.com/

Read More

Who are in the management team of Atea Pharmaceuticals, Inc.?

22-Jun-2025

As of March 2022, the management team of Atea Pharmaceuticals, Inc. is led by Mr. Jean-Pierre Sommadossi, who is the Chairman of the Board, Chief Executive Officer, and Founder.

As of March 2022, the management team of Atea Pharmaceuticals, Inc. includes Mr. Jean-Pierre Sommadossi, who serves as the Chairman of the Board, Chief Executive Officer, and Founder of the company.

Read More

Is Atea Pharmaceuticals, Inc. overvalued or undervalued?

25-Jun-2025

As of February 28, 2023, Atea Pharmaceuticals, Inc. is considered overvalued with significant financial concerns, reflected in its negative P/E ratio, low Price to Book Value, and unfavorable comparison to peers, despite a recent stock performance that outpaced the S&P 500.

As of 28 February 2023, Atea Pharmaceuticals, Inc. has moved from a fair valuation to a status of does not qualify, indicating significant concerns regarding its financial health and market position. The company is currently deemed overvalued, particularly given its negative P/E ratio due to losses, a Price to Book Value of 0.66, and an EV to EBITDA of 0.94. These metrics suggest that the company's valuation does not align with its financial performance.<BR><BR>In comparison to its peers, Atea Pharmaceuticals' valuation appears unfavorable. For instance, Soleno Therapeutics, Inc. has a significantly lower EV to EBITDA ratio of -18.16, while Phibro Animal Health Corp. stands out as very attractive with a P/E ratio of 21.68. Additionally, Atea's ROE stands at -33.93%, which further underscores its struggles relative to the industry. The recent stock performance shows a 1-month return of 14.48%, outperforming the S&P 500's 3.83%, but this does not mitigate the overall valuation concerns.

Read More

Is Atea Pharmaceuticals, Inc. technically bullish or bearish?

20-Sep-2025

As of September 12, 2025, Atea Pharmaceuticals' technical trend is neutral with mixed indicators, showing a shift from mildly bullish to sideways, while significantly underperforming the S&P 500 with a 1-year return of -25.56%.

As of 12 September 2025, the technical trend for Atea Pharmaceuticals, Inc. has changed from mildly bullish to sideways. The current stance is neutral, with mixed indicators influencing this position. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish. However, both the weekly and monthly Bollinger Bands indicate a bearish trend. The daily moving averages show a mildly bullish signal, but the KST and OBV metrics are both mildly bearish on the weekly and monthly timeframes. <BR><BR>In terms of performance, Atea Pharmaceuticals has underperformed significantly compared to the S&P 500 across multiple periods, with a 1-year return of -25.56% versus the S&P's 17.14%.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 258 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.04

stock-summary
Return on Equity

-37.35%

stock-summary
Price to Book

0.71

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-37 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
24.83%
0%
24.83%
6 Months
7.1%
0%
7.1%
1 Year
11.38%
0%
11.38%
2 Years
14.92%
0%
14.92%
3 Years
-21.13%
0%
-21.13%
4 Years
-60.26%
0%
-60.26%
5 Years
-89.5%
0%
-89.5%

Atea Pharmaceuticals, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-237.63%
EBIT to Interest (avg)
-79.08
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.03
Sales to Capital Employed (avg)
0.29
Tax Ratio
0.65%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
75.98%
ROCE (avg)
0
ROE (avg)
2.23%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.66
EV to EBIT
0.94
EV to EBITDA
0.94
EV to Capital Employed
11.26
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
1197.73%
ROE (Latest)
-33.93%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 41 Schemes (27.59%)

Foreign Institutions

Held by 50 Foreign Institutions (5.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 8.15% vs -43.62% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-41.20",
          "val2": "-46.80",
          "chgp": "11.97%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-37.20",
          "val2": "-40.50",
          "chgp": "8.15%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -23.82% vs -17.34% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-192.50",
          "val2": "-163.70",
          "chgp": "-17.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-168.40",
          "val2": "-136.00",
          "chgp": "-23.82%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-41.20
-46.80
11.97%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-37.20
-40.50
8.15%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 8.15% vs -43.62% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-192.50
-163.70
-17.59%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-168.40
-136.00
-23.82%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -23.82% vs -17.34% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Atea Pharmaceuticals, Inc. stock-summary
stock-summary
Atea Pharmaceuticals, Inc.
Pharmaceuticals & Biotechnology
Atea Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing antiviral therapeutics to improve the lives of patients suffering from life-threatening viral infections. It is focused on development of orally available selective nucleotide prodrugs for difficult-to-treat, life-threatening viral infections, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Its lead product candidate, AT-527, is an orally administered, antiviral agent for the treatment of patients infected with SARS-CoV-2. It provides AT-787 for the treatment of hepatitis C. It offers AT-752 for the treatment of dengue, which is an oral, purine nucleotide prodrug for the treatment of dengue virus, a mosquito-borne viral infection. The Company is evaluating two lead compounds, AT-889 and AT-934, nucleoside pyrimidine prodrugs and other compounds for the treatment of respiratory syncytial virus (RSV).
Company Coordinates stock-summary
Company Details
125 SUMMER STREET, 16TH FLOOR , BOSTON MA : 02110
stock-summary
Tel: 1 857 2048109
stock-summary
https://ateapharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."